Published in Mol Psychiatry on January 01, 2002
Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry (2010) 2.00
Single nucleotide polymorphisms (SNPs) distinguish Indian-origin and Chinese-origin rhesus macaques (Macaca mulatta). BMC Genomics (2007) 1.87
Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis. Mol Psychiatry (2013) 1.86
The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet (2005) 1.70
A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A (2006) 1.40
Attention-Deficit Hyperactivity Disorder in the post-genomic era. Eur Child Adolesc Psychiatry (2004) 1.36
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet (2005) 1.08
Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol (2006) 1.05
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology (2012) 1.03
Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood. Neurosci Biobehav Rev (2011) 1.00
A review on experimental and clinical genetic associations studies on fear conditioning, extinction and cognitive-behavioral treatment. Transl Psychiatry (2011) 0.97
A family based association study of DRD4, DAT1, and 5HTT and continuous traits of attention-deficit hyperactivity disorder. Behav Genet (2011) 0.96
Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS). Mol Neurobiol (2014) 0.96
Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects. Addict Biol (2011) 0.94
New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet (2009) 0.93
Functional genomics of attention-deficit/hyperactivity disorder (ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects. Biol Psychiatry (2012) 0.91
Molecular variation at the SLC6A3 locus predicts lifetime risk of PTSD in the Detroit Neighborhood Health Study. PLoS One (2012) 0.91
Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. Psychopharmacology (Berl) (2004) 0.90
Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population. PLoS One (2014) 0.89
The genetics of nicotine dependence: relationship to pancreatic cancer. World J Gastroenterol (2006) 0.88
Dopamine transporter (SLC6A3) genotype impacts neurophysiological correlates of cognitive response control in an adult sample of patients with ADHD. Neuropsychopharmacology (2010) 0.87
Monoamine transporters: vulnerable and vital doorkeepers. Prog Mol Biol Transl Sci (2011) 0.87
From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl) (2004) 0.85
Polymorphisms in genes modulating the dopamine system: do they inf luence outcome and response to medication after traumatic brain injury? J Head Trauma Rehabil (2009) 0.85
Cognitive effects of nicotine: genetic moderators. Addict Biol (2010) 0.85
Large-scale polymorphism discovery in macaque G-protein coupled receptors. BMC Genomics (2013) 0.84
Altered metabolic signature in pre-diabetic NOD mice. PLoS One (2012) 0.83
Variation in genes involved in dopamine clearance influence the startle response in older adults. J Neural Transm (Vienna) (2011) 0.83
Effect of dopamine transporter genotype on caudate volume in childhood ADHD and controls. Am J Med Genet B Neuropsychiatr Genet (2010) 0.82
Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol (2007) 0.82
The genetic studies of obsessive-compulsive disorder and its future directions. Yonsei Med J (2006) 0.80
Human dopamine transporter gene: differential regulation of 18-kb haplotypes. Pharmacogenomics (2013) 0.79
DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics. Pharmgenomics Pers Med (2010) 0.79
In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions. BMC Genomics (2007) 0.79
Association between amygdala reactivity and a dopamine transporter gene polymorphism. Transl Psychiatry (2014) 0.78
c.822+126T>G/C: a novel triallelic polymorphism of the TSSK6 gene associated with spermatogenic impairment in a Chinese population. Asian J Androl (2009) 0.78
Dopamine transporter (DAT1) and dopamine receptor D4 (DRD4) genotypes differentially impact on electrophysiological correlates of error processing. PLoS One (2011) 0.78
Lack of association between polymorphisms of the dopamine receptor D4 and dopamine transporter genes and personality traits in a Korean population. Yonsei Med J (2006) 0.78
Association of dopamine transporter gene variants with childhood ADHD features in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2012) 0.77
Comparative genetic approaches to the evolution of human brain and behavior. Am J Hum Biol (2010) 0.76
Neural Correlates of Exposure to Cocaine Cues in Rhesus Monkeys: Modulation by the Dopamine Transporter. Biol Psychiatry (2016) 0.76
Dopamine transporter gene susceptibility to methylation is associated with impulsivity in nonhuman primates. J Neurophysiol (2014) 0.76
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet (2015) 0.76
Using iPSC-derived human DA neurons from opioid-dependent subjects to study dopamine dynamics. Brain Behav (2016) 0.76
Child dopamine active transporter 1 genotype and parenting: evidence for evocative gene-environment correlations. Dev Psychopathol (2013) 0.75
Acute oral administration of low doses of methylphenidate targets calretinin neurons in the rat septal area. Front Neuroanat (2015) 0.75
Dopamine transporter (DAT1) VNTR polymorphism in 12 Indian populations. Neurol Sci (2009) 0.75
Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet (2000) 2.95
Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther (1989) 2.04
Asparagine synthetase activity of mouse leukemias. Science (1968) 1.49
Serum tryptophan level after carbohydrate ingestion: selective decline in non-albumin-bound tryptophan coincident with reduction in serum free fatty acids. Life Sci II (1973) 1.38
Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry (1998) 1.35
The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J Med Chem (1994) 1.28
A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol Psychiatry (2004) 1.25
Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse (1991) 1.18
Relevance of free tryptophan in serum to tissue tryptophan concentrations. Metabolism (1974) 1.16
Letter: Dietary carbohydrate increases brain tryptophan and decreases free plasma tryptophan. Nature (1973) 1.13
Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther (1989) 1.10
Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Brain Res Mol Brain Res (2001) 0.99
2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters. J Med Chem (1997) 0.97
Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism. Neuroreport (1992) 0.95
Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters. J Med Chem (2001) 0.95
Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther (1991) 0.95
Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders. Mol Psychiatry (2001) 0.93
Formation of respiratory 14CO2 from variously labeled forms of tryptophan-14C in intact and adrenalectomized rats. Arch Biochem Biophys (1968) 0.90
Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain. Synapse (1990) 0.90
[(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse (2001) 0.90
Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. Synapse (1991) 0.88
Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J Med Chem (1993) 0.88
Effect of yohimbine on tryptophan metabolism. J Pharmacol Exp Ther (1969) 0.86
Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse (1998) 0.85
[3H]WIN 35,428 ([3H]CFT) binds to multiple charge-states of the solubilized dopamine transporter in primate striatum. J Pharmacol Exp Ther (1995) 0.84
[(3)H]PNU-101958, a D(4) dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. Synapse (2000) 0.84
Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol (2006) 0.84
Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT. Synapse (1996) 0.83
Bicyclo[3.2.1]octanes: synthesis and inhibition of binding at the dopamine and serotonin transporters. Bioorg Med Chem Lett (1999) 0.83
Behavioral effects of D1 and D2 dopamine receptor antagonists in squirrel monkeys. J Pharmacol Exp Ther (1991) 0.82
Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) (2001) 0.82
A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem (1997) 0.82
Effects of skim milk, whole milk and light cream on serum tryptophan binding and brain tryptophan concentrations in rats. J Nutr (1975) 0.81
Concentration of dopamine transporters: to Bmax or not to Bmax? Synapse (1999) 0.81
Effects of drugs on the metabolism of tryptophan. Alpha-hydrazinotryptophan and other amino acid analogs. Biochem Pharmacol (1968) 0.80
Metabolism of alpha-methyltryptophan. Biochem Pharmacol (1965) 0.80
Distribution of cocaine recognition sites in monkey brain: II. Ex vivo autoradiography with [3H]CFT and [125I]RTI-55. Synapse (1992) 0.80
Role of D1 and D2 dopamine receptors in the behavioral effects of cocaine. Neurochem Int (1992) 0.80
Cocaine congeners as PET imaging probes for dopamine terminals. J Nucl Med (1996) 0.80
D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates. J Pharmacol Exp Ther (2000) 0.80
2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters. J Med Chem (2000) 0.80
Non-amine dopamine transporter probe [(3)H]tropoxene distributes to dopamine-rich regions of monkey brain. Synapse (1999) 0.80
Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands. J Med Chem (1991) 0.80
D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther (2000) 0.79
3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter. Bioorg Med Chem (2000) 0.79
11C-WIN 35,428 for detecting dopamine depletion in mild Parkinson's disease. Ann Neurol (1994) 0.79
Synthesis and preliminary characterization of a high-affinity novel radioligand for the dopamine transporter. Synapse (2001) 0.78
2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series. J Med Chem (1996) 0.78
A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures. Cell Transplant (1992) 0.78
Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites. J Nucl Med (1996) 0.77
Solubilized dopamine/neuroleptic receptors (D2-type). Prog Neuropsychopharmacol (1981) 0.77
Assay for soluble dopamine receptors by the precipitation method. Eur J Pharmacol (1981) 0.77
Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites. Psychopharmacology (Berl) (1992) 0.77
Comparison of soluble dopamine D2-receptors from three species. Eur J Pharmacol (1982) 0.77
Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys. J Pharmacol Exp Ther (1996) 0.77
Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse (2001) 0.77
[3H]CFT ([3H]WIN 35,428) accumulation in dopamine regions of monkey brain: comparison of a mature and an aged monkey. Brain Res (1993) 0.77
Drug potencies on partially purified brain D2 dopamine receptors. J Neurochem (1985) 0.76
[3H]Mianserin binding to solubilized membranes of frontal cortex. Eur J Pharmacol (1982) 0.76
Elevation of serum free tryptophan, but not brain tryptophan, by serum nonesterified fatty acids. Adv Biochem Psychopharmacol (1974) 0.76
Solubilized receptors for [3H]dopamine (D3 binding sites) from canine brain. Biochem Pharmacol (1982) 0.76
PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol (1994) 0.75
Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med (1997) 0.75
Saturable binding of [3H]phenytoin to rat brain membrane fraction. Can J Physiol Pharmacol (1981) 0.75
Alan Horn Memorial Lecture. Selective probes for characterization of dopamine D1 and D2 receptors. Neurochem Int (1992) 0.75
Direct binding assays in determining psychotropic drug mechanism of action. Rev Pure Appl Pharmacol Sci (1987) 0.75
Synthesis and receptor binding of N-substituted tropane derivatives. High-affinity ligands for the cocaine receptor. J Med Chem (1991) 0.75
Partial purification of [3H]mianserin binding sites. Eur J Pharmacol (1983) 0.75
Enhancement of 3H-phenytoin binding by diazepam and (+)bicuculline. Life Sci (1983) 0.75
Ascorbate injury and EDTA (or manganese) protection of D2-dopamine receptors. Eur J Pharmacol (1982) 0.75
Self-administration of the high-affinity cocaine analog 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Pharmacol Biochem Behav (1991) 0.75
Modulation of dopamine receptor binding by ascorbic acid. Adv Biochem Psychopharmacol (1983) 0.75
SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys. J Nucl Med (1997) 0.75